Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report

Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histolog...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2024, pp.3155-23
Main Authors: Suzuki, Nobumi, Odawara, Nariaki, Fujisawa, Gota, Ishibashi, Rei, Hata, Masahiro, Oya, Yukiko, Tamada, Kenji, Hayashi, Takeshi, Abe, Sohei, Miyakawa, Yu, Hayakawa, Yoku, Shinozaki-Ushiku, Aya, Ushiku, Tetsuo, Boku, Narikazu, Fujishiro, Mitsuhiro
Format: Article
Language:English
Subjects:
gastric adenocarcinoma with enteroblastic differentiation
gastric cancer
HER2
trastuzumab deruxtecan
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 3155-23
container_title Internal Medicine
container_volume
creator Suzuki, Nobumi
Odawara, Nariaki
Fujisawa, Gota
Ishibashi, Rei
Hata, Masahiro
Oya, Yukiko
Tamada, Kenji
Hayashi, Takeshi
Abe, Sohei
Miyakawa, Yu
Hayakawa, Yoku
Shinozaki-Ushiku, Aya
Ushiku, Tetsuo
Boku, Narikazu
Fujishiro, Mitsuhiro
description Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.
doi_str_mv 10.2169/internalmedicine.3155-23
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3065276894</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3065276894</sourcerecordid><originalsourceid>FETCH-LOGICAL-j2513-3bb09f3a1d8b6cda0d29133e4c052729adbdd94c347b0f3b5896433119a5f3aa3</originalsourceid><addsrcrecordid>eNpdks9u1DAQxi0EokvhFZCP5ZA2ySTZmNtqd9lWqlRUCtdoEk-oV4kdbKf8eU_eh1lt2wMX25K_-fmb-SyEzNLzPKvUhbGRvMVhJG06Y-kcsrJMcnghFhkUKlnmUL4Ui1RldZLzciLehLBPU6iXKn8tTqCuQQGUC_H3yxwiMkLL9WCs6XCQazdOA0WStxQmZwNJ7Pk9uTGhczYaO2M0zkrXyzuPIc5_5hHbRJOff3FZh1ZuZpLRyauDzxBNNIz9bGkenTUoe-fl5fY2TyYX-O6B5I4x3nQSNVnXoeem3Ijyp4n3cnuAuHZgCSs2pu_JE9s4mjjbrbabDx_lSq4xHCxPzse34lWPQ6B3j_up-Pppe7e-TK5vdlfr1XWyz8sMEmjbVPWAma7bqtOYah4WABVdWubLXKFutVZFB8WyTXtoy1pVBUCWKSy5DOFUnB25k3c_ZgqxGXlGNAxoyc2hgbRiUFWrgqXvH6Vzy7E1kzcj-t_NUxQs-HYU7DmQ7_QsQM9tD9T8n3mD-oFZTfp0OPyBJofngu4efUMW_gFYxbXf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3065276894</pqid></control><display><type>article</type><title>Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report</title><source>Open Access: PubMed Central</source><creator>Suzuki, Nobumi ; Odawara, Nariaki ; Fujisawa, Gota ; Ishibashi, Rei ; Hata, Masahiro ; Oya, Yukiko ; Tamada, Kenji ; Hayashi, Takeshi ; Abe, Sohei ; Miyakawa, Yu ; Hayakawa, Yoku ; Shinozaki-Ushiku, Aya ; Ushiku, Tetsuo ; Boku, Narikazu ; Fujishiro, Mitsuhiro</creator><creatorcontrib>Suzuki, Nobumi ; Odawara, Nariaki ; Fujisawa, Gota ; Ishibashi, Rei ; Hata, Masahiro ; Oya, Yukiko ; Tamada, Kenji ; Hayashi, Takeshi ; Abe, Sohei ; Miyakawa, Yu ; Hayakawa, Yoku ; Shinozaki-Ushiku, Aya ; Ushiku, Tetsuo ; Boku, Narikazu ; Fujishiro, Mitsuhiro</creatorcontrib><description>Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.3155-23</identifier><identifier>PMID: 38839335</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>gastric adenocarcinoma with enteroblastic differentiation ; gastric cancer ; HER2 ; trastuzumab deruxtecan</subject><ispartof>Internal Medicine, 2024, pp.3155-23</ispartof><rights>2024 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38839335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Nobumi</creatorcontrib><creatorcontrib>Odawara, Nariaki</creatorcontrib><creatorcontrib>Fujisawa, Gota</creatorcontrib><creatorcontrib>Ishibashi, Rei</creatorcontrib><creatorcontrib>Hata, Masahiro</creatorcontrib><creatorcontrib>Oya, Yukiko</creatorcontrib><creatorcontrib>Tamada, Kenji</creatorcontrib><creatorcontrib>Hayashi, Takeshi</creatorcontrib><creatorcontrib>Abe, Sohei</creatorcontrib><creatorcontrib>Miyakawa, Yu</creatorcontrib><creatorcontrib>Hayakawa, Yoku</creatorcontrib><creatorcontrib>Shinozaki-Ushiku, Aya</creatorcontrib><creatorcontrib>Ushiku, Tetsuo</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Fujishiro, Mitsuhiro</creatorcontrib><title>Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.</description><subject>gastric adenocarcinoma with enteroblastic differentiation</subject><subject>gastric cancer</subject><subject>HER2</subject><subject>trastuzumab deruxtecan</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdks9u1DAQxi0EokvhFZCP5ZA2ySTZmNtqd9lWqlRUCtdoEk-oV4kdbKf8eU_eh1lt2wMX25K_-fmb-SyEzNLzPKvUhbGRvMVhJG06Y-kcsrJMcnghFhkUKlnmUL4Ui1RldZLzciLehLBPU6iXKn8tTqCuQQGUC_H3yxwiMkLL9WCs6XCQazdOA0WStxQmZwNJ7Pk9uTGhczYaO2M0zkrXyzuPIc5_5hHbRJOff3FZh1ZuZpLRyauDzxBNNIz9bGkenTUoe-fl5fY2TyYX-O6B5I4x3nQSNVnXoeem3Ijyp4n3cnuAuHZgCSs2pu_JE9s4mjjbrbabDx_lSq4xHCxPzse34lWPQ6B3j_up-Pppe7e-TK5vdlfr1XWyz8sMEmjbVPWAma7bqtOYah4WABVdWubLXKFutVZFB8WyTXtoy1pVBUCWKSy5DOFUnB25k3c_ZgqxGXlGNAxoyc2hgbRiUFWrgqXvH6Vzy7E1kzcj-t_NUxQs-HYU7DmQ7_QsQM9tD9T8n3mD-oFZTfp0OPyBJofngu4efUMW_gFYxbXf</recordid><startdate>20240606</startdate><enddate>20240606</enddate><creator>Suzuki, Nobumi</creator><creator>Odawara, Nariaki</creator><creator>Fujisawa, Gota</creator><creator>Ishibashi, Rei</creator><creator>Hata, Masahiro</creator><creator>Oya, Yukiko</creator><creator>Tamada, Kenji</creator><creator>Hayashi, Takeshi</creator><creator>Abe, Sohei</creator><creator>Miyakawa, Yu</creator><creator>Hayakawa, Yoku</creator><creator>Shinozaki-Ushiku, Aya</creator><creator>Ushiku, Tetsuo</creator><creator>Boku, Narikazu</creator><creator>Fujishiro, Mitsuhiro</creator><general>The Japanese Society of Internal Medicine</general><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20240606</creationdate><title>Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report</title><author>Suzuki, Nobumi ; Odawara, Nariaki ; Fujisawa, Gota ; Ishibashi, Rei ; Hata, Masahiro ; Oya, Yukiko ; Tamada, Kenji ; Hayashi, Takeshi ; Abe, Sohei ; Miyakawa, Yu ; Hayakawa, Yoku ; Shinozaki-Ushiku, Aya ; Ushiku, Tetsuo ; Boku, Narikazu ; Fujishiro, Mitsuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j2513-3bb09f3a1d8b6cda0d29133e4c052729adbdd94c347b0f3b5896433119a5f3aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>gastric adenocarcinoma with enteroblastic differentiation</topic><topic>gastric cancer</topic><topic>HER2</topic><topic>trastuzumab deruxtecan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Nobumi</creatorcontrib><creatorcontrib>Odawara, Nariaki</creatorcontrib><creatorcontrib>Fujisawa, Gota</creatorcontrib><creatorcontrib>Ishibashi, Rei</creatorcontrib><creatorcontrib>Hata, Masahiro</creatorcontrib><creatorcontrib>Oya, Yukiko</creatorcontrib><creatorcontrib>Tamada, Kenji</creatorcontrib><creatorcontrib>Hayashi, Takeshi</creatorcontrib><creatorcontrib>Abe, Sohei</creatorcontrib><creatorcontrib>Miyakawa, Yu</creatorcontrib><creatorcontrib>Hayakawa, Yoku</creatorcontrib><creatorcontrib>Shinozaki-Ushiku, Aya</creatorcontrib><creatorcontrib>Ushiku, Tetsuo</creatorcontrib><creatorcontrib>Boku, Narikazu</creatorcontrib><creatorcontrib>Fujishiro, Mitsuhiro</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Nobumi</au><au>Odawara, Nariaki</au><au>Fujisawa, Gota</au><au>Ishibashi, Rei</au><au>Hata, Masahiro</au><au>Oya, Yukiko</au><au>Tamada, Kenji</au><au>Hayashi, Takeshi</au><au>Abe, Sohei</au><au>Miyakawa, Yu</au><au>Hayakawa, Yoku</au><au>Shinozaki-Ushiku, Aya</au><au>Ushiku, Tetsuo</au><au>Boku, Narikazu</au><au>Fujishiro, Mitsuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2024-06-06</date><risdate>2024</risdate><spage>3155-23</spage><pages>3155-23-</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Trastuzumab deruxtecan (T-DXd) has demonstrated remarkable efficacy as a third- or later-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric and gastroesophageal junction adenocarcinomas. However, it may cause pneumonitis, and its efficacy in rare histologies such as gastric adenocarcinoma with enteroblastic differentiation (GAED) remains unclear. A 74-year-old woman with unresectable HER2-positive GAED and lung metastasis received T-DXd as a fifth-line chemotherapy. Treatment was discontinued after 15 cycles owing to drug-induced pneumonitis; however, the patient achieved a sustained complete response for 14 months without subsequent chemotherapy or the exacerbation of pneumonitis. T-DXd was effective in HER2-positive GAED.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>38839335</pmid><doi>10.2169/internalmedicine.3155-23</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-2918
ispartof Internal Medicine, 2024, pp.3155-23
issn 0918-2918
1349-7235
language eng
recordid cdi_proquest_miscellaneous_3065276894
source Open Access: PubMed Central
subjects gastric adenocarcinoma with enteroblastic differentiation
gastric cancer
HER2
trastuzumab deruxtecan
title Sustained Clinical Complete Response after Discontinuation of Trastuzumab-deruxetecan Due to Interstitial Pneumonia for HER2-positive Gastric adenocarcinoma with Enteroblastic Differentiation (GAED): A Case Report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T14%3A36%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sustained%20Clinical%20Complete%20Response%20after%20Discontinuation%20of%20Trastuzumab-deruxetecan%20Due%20to%20Interstitial%20Pneumonia%20for%20HER2-positive%20Gastric%20adenocarcinoma%20with%20Enteroblastic%20Differentiation%20(GAED):%20A%20Case%20Report&rft.jtitle=Internal%20Medicine&rft.au=Suzuki,%20Nobumi&rft.date=2024-06-06&rft.spage=3155-23&rft.pages=3155-23-&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.3155-23&rft_dat=%3Cproquest_pubme%3E3065276894%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j2513-3bb09f3a1d8b6cda0d29133e4c052729adbdd94c347b0f3b5896433119a5f3aa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3065276894&rft_id=info:pmid/38839335&rfr_iscdi=true